Related references
Note: Only part of the references are listed.Disparity between ultrasound and clinical findings in psoriatic arthritis
Rusmir Husic et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Development of a Disease Activity and Responder Index for Psoriatic Arthritis - Report of the Psoriatic Arthritis Module at OMERACT 11
Laura C. Coates et al.
JOURNAL OF RHEUMATOLOGY (2014)
Disease Activity in Psoriatic Arthritis: Comparison of the Discriminative Capacity and Construct Validity of Six Composite Indices in a Real World
Fausto Salaffi et al.
BIOMED RESEARCH INTERNATIONAL (2014)
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)
Philip S. Helliwell et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index
Daniel Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Development of a preliminary composite disease activity index in psoriatic arthritis
Aizad Mumtaz et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis
Valerie P. Nell-Duxneuner et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis
Monika Schoels et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
J. S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Rheumatoid Arthritis Joint Progression in Sustained Remission Is Determined by Disease Activity Levels Preceding the Period of Radiographic Assessment
D. Aletaha et al.
ARTHRITIS AND RHEUMATISM (2009)
Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2009)
Psoriatic Arthritis - Current concepts on pathogenesis-oriented therapeutic options
Anthony M. Turkiewicz et al.
ARTHRITIS AND RHEUMATISM (2007)
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors
J. Fransen et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2005)
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
C Antoni et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
CE Antoni et al.
ARTHRITIS AND RHEUMATISM (2005)
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
D Aletaha et al.
ARTHRITIS RESEARCH & THERAPY (2005)
A simplified disease activity index for rheumatoid arthritis for use in clinical practice
JS Smolen et al.
RHEUMATOLOGY (2003)
Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis
LC Doward et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Development of a disease activity index for the assessment of reactive arthritis (DAREA)
G Eberl et al.
RHEUMATOLOGY (2000)
Share Paper
